Antiosteoporotic Effect of Fisetin in an Estrogen Deficient Model of Osteoporosis

Background: Osteoporosis is a serious health problem, especially in the geriatric populations. World widely, it exaggerated the 8.9 million people every year roughly. In the current analysis, we assessed the antiosteoporotic effect of fisetin on the osteoporosis model ovariectomized (OVX) rat. Materials and Methods: Fisetin was orally administrated at dose of 5, 10, and 20 mg/kg to OVX rats for 16 weeks. Different biochemical parameters such as alkaline phosphatase (ALP), osteocalcin, phosphorus, calcium, and urinary deoxypyridinoline were also projected. 3‑point bending test, bone mineral density (BMD), and histomorphometric feature of the femoral bone were also examined. Results: Fisetin significantly decreased the body weight and increased the uterine weight. A significant decrease detected in the level of ALP, serum calcium, while the level of the serum phosphorus, OC augmented after fisetin administration. Fisetin significantly (P < 0.001) reduced the homocysteine, C‑terminal crosslinked telopeptides of collagen type I, interferon gamma, and increased the level of OC. Fisetin also augmented the level of BMD. Fisetin considerably increased the energy, maximum load, maximum stress, young modulus, and stiffness. The level of cytokines such as tumor necrosis factor‑α, interleukin (IL)‑6, and IL‑1 β also diminished pointedly after fisetin treatment. Fisetin significantly boosted the estrogen (E2) level and reduced the level of follicle‑stimulating hormone and luteinizing hormone. Conclusion: Communally, we can accomplish that fisetin exhibited the better protection against osteoporosis through augmenting the bone density and bone mineral content in addition to biomechanical parameters.